Paris, November 5 (ots/PRNewswire) – Sanofi-aventis announced today that it is a partner in a new multidisciplinary atrial fibrillation research consortium, the “European Network for Translational research in Atrial Fibrillation” (EUTRAF), which has been awarded a EUR12 million grant to engage in atrial fibrillation (AF) research. The European consortium is commencing a five-year research project [...]
Tag Archive > Marc Cluzel
Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
Paris (ots/PRNewswire) – Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta). Teriflunomide is a novel oral disease modifier developed by sanofi-aventis which [...]
Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
Paris (ots/PRNewswire) – Sanofi-aventis announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate (primary study endpoint) by 31% vs. placebo (p [...]
Covance und Sanofi-Aventis unterzeichnen Vertrag über 10-jährige Zusammenarbeit im F&E-Bereich
Princeton, New Jersey (ots/PRNewswire) – Covance Inc. gab heute die Unterzeichnung von Verträgen mit sanofi-aventis bekannt, nach denen Covance ein F&E-Partner von sanofi-aventis wird. In den kommenden zehn Jahren erwartet Covance, sanofi-aventis Dienstleistungen zur Arzneimittelentwicklung anzubieten, und rechnet mit Einnahmen zwischen 1,2 und 2,2 Milliarden USD. Sanofi-aventis verkauft seine Niederlassungen in Porcheville (Frankreich) und Alnwick [...]
Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
Paris, November 30 (ots/PRNewswire) – – First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Commission has granted marketing authorization for Multaq(R) (dronedarone – 400mg Tablets) in all 27 European member states. This approval follows the European [...]
